Drugs / HLX60
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05483530 | Dec 2022 → Dec 2024 | — | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 1 | NCT05606380 | Dec 2022 → Aug 2024 | lymphoma | Shanghai Henlius Biotech | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX60 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05483530 ↗ |
| Modality | Monoclonal antibody | “HLX60 (Anti-GARP Monoclonal Antibody)” NCT05483530 ↗ |
| Route | Intravenous | “intravenous infusion” NCT05606380 ↗ |